Hologic (HOLX)
(Delayed Data from NSDQ)
$67.16 USD
+0.34 (0.51%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $65.86 -1.30 (-1.94%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth A Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
HOLX 67.16 +0.34(0.51%)
Will HOLX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for HOLX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HOLX
Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings
Hologic Stock Falls Despite Q3 Earnings and Revenue Beat, Margins Down
HOLX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Compared to Estimates, Hologic (HOLX) Q3 Earnings: A Look at Key Metrics
Hologic (HOLX) Q3 Earnings and Revenues Beat Estimates
Hologic Focuses on Breast Health Turnaround This Year: Can It Deliver?
Other News for HOLX
Hologic (HOLX) Price Target Increased by Morgan Stanley
Hologic price target raised by $4 at Morgan Stanley, here's why
Meta, Microsoft Power Wall Street To New Records Despite Inflation Jump: What's Moving Markets Thursday?
Decoding Hologic Inc (HOLX): A Strategic SWOT Insight
Hologic (HOLX) Sees Price Target Raised by Morgan Stanley | HOLX Stock News